Live Breaking News & Updates on Cell Therapy Innovations

Stay updated with breaking news from Cell therapy innovations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IMU Biosciences raises £11.5 million Series A

We are delighted to announce that Molten Ventures has led a £11.5 million Series A funding round in IMU Biosciences, a techbio company revolutionising immune powered precision medicine.
IMU. ....

United States , City Of , United Kingdom , Tim Haines , Oliver Nussbaumer , Adrian Hayday , Mario Cantero , Inga Deakin , Adam Laing , Adaptate Biotherapeutics , Tom Hayday , King College London , Duke University , Francis Crick Institute , Non Executive Chair , Executive Partner , Executive Scientific Director , Cell Therapy Innovations , Delta Therapeutics , Chief Executive Officer , Chief Scientific Officer , Chief Operating Officer , College London ,

IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine

IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , City Of , Oliver Nussbaumer , Frazer Hall , Leila Adlam , Inga Deakin , Tim Haines Abingworth , Adam Laing , Tom Hayday , Tim Haines , Mario Cantero , Adaptate Biotherapeutics , Entrepreneur In Residence At Duke University , Professor Adrian Hayday At King College London , Head Of Communications , Non Executive Chair , Gammadelta Therapeutics , Molten Ventures , Lifex Ventures , Executive Partner , Executive Scientific Director , Cell Therapy Innovations , Chief Executive Officer , Chief Scientific Officer , Chief Operating Officer , Professor Adrian Hayday ,